Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

Core Insights - Provectus Biopharmaceuticals has initiated a preclinical study for its investigational drug PV-10 targeting bladder cancer, with results anticipated in Q1 2026 [1][2] - The study will assess PV-10's efficacy through various treatment methods, including oral and intravesical monotherapy, as well as in combination with an anti-PD-1 checkpoint inhibitor [2] - Successful outcomes from this research could lead to an expanded investigational new drug application for PV-10, potentially transforming treatment options for solid tumor and hematologic cancers [3] Company Overview - Provectus Biopharmaceuticals is a clinical-stage biotechnology firm focused on developing immunotherapy treatments based on rose bengal sodium, a synthetic small molecule [4] - The company's clinical programs encompass oncology, dermatology, and ophthalmology, with additional initiatives in hematology, wound healing, infectious diseases, and tissue repair [4]